Captrust Financial Advisors Gemini Therapeutics, Inc. Call Options Transaction History

Captrust Financial Advisors

  • $33 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding GMTX

# of Institutions
1
Shares Held
2.44M
Call Options Held
0
Put Options Held
0
View Full List

About Gemini Therapeutics, Inc.

GMTX Quotes by TradingView
  • Ticker GMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,244,500
  • Market Cap $1.05B
  • Description
  • Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...
More about GMTX
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email